Loading...
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action t...
Na minha lista:
| Udgivet i: | World J Gastroenterol |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Baishideng Publishing Group Inc
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6010939/ https://ncbi.nlm.nih.gov/pubmed/29930467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v24.i23.2457 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|